Critical Mass: Daubert in New Jersey. Plus Do-Overs For Diabetes Suits and When 'Chutzpah' Doesn't Pay

Tangle Over Science: New Jersey is set to become a battleground over the quality of scientific evidence to be presented to juries in a Big Pharma case--this one over Accutane, the anti-acne drug which plaintiffs have linked to Crohn's disease. But the appeal isn't just about Accutane. There are amicus briefs calling on the New Jersey Supreme Court to adopt the Daubert standard, which is often seen as more defense-friendly.

December 13, 2017 at 07:00 AM

6 minute read

Welcome to Critical Mass, Law.com's new briefing on class actions and mass torts. I'm Amanda Bronstad in Los Angeles. This week, the New Jersey Supreme Court takes up a battle over experts, and a federal judge freezes out some outside funders in the NFL concussion settlement. Hundreds of lawsuits over a diabetes drug were revived by a 9th Circuit panel. Also, find out what made the 7th Circuit criticize a case for being “emblematic of what is wrong with class actions.”

Want to subscribe? This briefing—and others written by my Law.com colleagues—are now available. You can sign up for a complimentary trial here. In the meantime, please send your feedback to [email protected] or find me on Twitter: @abronstadlaw.

Tangle Over Science Set in NJ Pharma Case

The New Jersey Supreme Court has agreed to hear an appeal in the litigation over Accutane, the anti-acne drug. Law.com's Michael Booth has the story.

Resources